Cell Therapeutics (CTIC) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cell Therapeutics (CTIC)

CTIC 9.090

0.0%

Jun 26 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Icebrg	5/25/2005 2:28:49 AM
	Read Replies (1) of 946

U.S. FDA warns of heart risks from Serono drug Wed May 25, 2005 01:35 AM ET ZURICH, May 25 (Reuters) - The U.S. Food and Drug Administration warned consumers and healthcare professionals of the risk of heart damage from Serono's (SEO.VX: Quote, Profile, Research) multiple sclerosis drug Novantrone. "Reports received through post-marketing surveillance have shown that diminished cardiac function may occur early on in the treatment with Novantrone," the FDA said in a statement posted on its Web site. It added that it had updated the product labelling for the drug. Novantrone is one of Serono's multiple sclerosis drugs, which the firm sells besides its flagship Rebif multiple sclerosis drug. Serono was not immediately available for comment. There used to be a small European Pixantrone program aimed at investigating the drug for the MS indication. As far as I know, this program was however stopped due to CTIC's limited cash position. Erik

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next